The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.
Selective phosphodiesterase inhibitors: a promising target for cognition enhancement
Open accessAbstract
RATIONALE: One of the major complaints most people face during aging is an impairment in cognitive functioning. This has a negative impact on the quality of daily life and is even more prominent in patients suffering from neurodegenerative and psychiatric disorders including Alzheimer's disease, schizophrenia, and depression. So far, the majority of cognition enhancers are generally targeting one particular neurotransmitter system. However, recently phosphodiesterases (PDEs) have gained increased attention as a potential new target for cognition enhancement. Inhibition of PDEs increases the intracellular availability of the second messengers cGMP and/or cAMP. OBJECTIVE: The aim of this review was to provide an overview of the effects of phosphodiesterase inhibitors (PDE-Is) on cognition, the possible underlying mechanisms, and the relationship to current theories about memory formation. MATERIALS AND METHODS: Studies of the effects of inhibitors of different PDE families (2, 4, 5, 9, and 10) on cognition were reviewed. In addition, studies related to PDE-Is and blood flow, emotional arousal, and long-term potentiation (LTP) were described. RESULTS: PDE-Is have a positive effect on several aspects of cognition, including information processing, attention, memory, and executive functioning. At present, these data are likely to be explained in terms of an LTP-related mechanism of action. CONCLUSION: PDE-Is are a promising target for cognition enhancement; the most suitable candidates appear to be PDE2-Is or PDE9-Is. The future for PDE-Is as cognition enhancers lies in the development of isoform-specific PDE-Is that have limited aversive side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566
Working memory: Looking back and looking forward
Baddeley, A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1201 · Cited by 5,200
Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
Bender, A. T., & Beavo, J. A. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.5 · Cited by 1,781
Blaney, P. H. (1986) · Psychological Bulletin · doi:10.1037//0033-2909.99.2.229 · Cited by 1,773
Protein synthesis and memory: A review.
Davis, H. P., & Squire, L. R. (1984) · Psychological Bulletin · doi:10.1037//0033-2909.96.3.518 · Cited by 1,503
β-Adrenergic activation and memory for emotional events
Cahill, L., Prins, B., Weber, M., & McGaugh, J. L. (1994) · Nature · doi:10.1038/371702a0 · Cited by 1,271
Cleavage of proBDNF by tPA/Plasmin Is Essential for Long-Term Hippocampal Plasticity
Pang, P. T., Teng, H. K., Zaitsev, E., Woo, N. T., Sakata, K., Zhen, S., Teng, K. K., Yung, W.-H., Hempstead, B. L., & Lu, B. (2004) · Science · doi:10.1126/science.1100135 · Cited by 1,136
The nitric oxide and cGMP signal transduction system: regulation and mechanism of action
Schmidt, H. H. H. W., Lohmann, S. M., & Walter, U. (1993) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(93)90006-b · Cited by 746
Synaptic plasticity in the hippocampus: LTP and LTD
Malenka, R. C. (1994) · Cell · doi:10.1016/0092-8674(94)90517-7 · Cited by 655
Impey, S., Mark, M., Villacres, E. C., Poser, S., Chavkin, C., & Storm, D. R. (1996) · Neuron · doi:10.1016/s0896-6273(00)80120-8 · Cited by 593
Cited by
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Keravis, T., & Lugnier, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01729.x · Cited by 385
Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species
Stephenson, D. T., Coskran, T. M., Wilhelms, M. B., Adamowicz, W. O., O'Donnell, M. M., Muravnick, K. B., Menniti, F. S., Kleiman, R. J., & Morton, D. (2009) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2009.953471 · Cited by 289
Endothelial nitric oxide deficiency promotes Alzheimer’s disease pathology
Austin, S. A., Santhanam, A. V., Hinton, D. J., Choi, D., & Katusic, Z. S. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12334 · Cited by 155
Metadata
- Authors
- Reneerkens, O. A. H., Rutten, K., Steinbusch, H. W. M., Blokland, A., & Prickaerts, J.
- Venue
- Psychopharmacology
- Published
- 2008-08-16
- Volume
- 202
- Issue
- 1-3
- Pages
- 419-443
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2004567605
- Cited by
- 266
- References
- 148
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. https://app.cochat.ai/papers/10.1007/s00213-008-1273-x
- The paper
- Reneerkens, O. A. H., Rutten, K., Steinbusch, H. W. M., Blokland, A., & Prickaerts, J. (2009). Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology. https://doi.org/10.1007/s00213-008-1273-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.